{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T19:39:40Z","timestamp":1772221180993,"version":"3.50.1"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100004206","name":"Osaka University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004206","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejpn-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Paediatric Neurology"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.ejpn.2025.02.003","type":"journal-article","created":{"date-parts":[[2025,2,11]],"date-time":"2025-02-11T17:08:42Z","timestamp":1739293722000},"page":"171-177","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Experience of nusinersen treatment in advanced spinal muscular atrophy type 1: Characteristics of late responders with delayed treatment efficacy"],"prefix":"10.1016","volume":"54","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7892-5968","authenticated-orcid":false,"given":"Sachi","family":"Tokunaga","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0815-9193","authenticated-orcid":false,"given":"Hideki","family":"Shimomura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takuya","family":"Horibe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoko","family":"Taniguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1064-1202","authenticated-orcid":false,"given":"Tomoko","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuhiro","family":"Takeshima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejpn.2025.02.003_bib1","doi-asserted-by":"crossref","first-page":"2120","DOI":"10.1016\/S0140-6736(08)60921-6","article-title":"Spinal muscular atrophy","volume":"371","author":"Lunn","year":"2008","journal-title":"Lancet."},{"key":"10.1016\/j.ejpn.2025.02.003_bib2","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1001\/archneurol.2011.74","article-title":"Spinal muscular atrophy: a timely review","volume":"68","author":"Kolb","year":"2011","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.ejpn.2025.02.003_bib3","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1056\/NEJMoa1702752","article-title":"Nusinersen versus sham control in infantile-onset spinal muscular atrophy","volume":"377","author":"Finkel","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejpn.2025.02.003_bib4","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/dmcn.14027","article-title":"Nusinersen treatment of spinal muscular atrophy: current knowledge and existing gaps","volume":"61","author":"Gidaro","year":"2019","journal-title":"Dev. Med. Child Neurol."},{"key":"10.1016\/j.ejpn.2025.02.003_bib5","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.jpeds.2019.12.047","article-title":"Respiratory needs in patients with Type 1 spinal muscular atrophy treated with nusinersen","volume":"219","author":"Sansone","year":"2020","journal-title":"J. Pediatr."},{"key":"10.1016\/j.ejpn.2025.02.003_bib6","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1097\/00003086-197707000-00006","article-title":"Scoliosis prevalence: a call for a statement of terms","author":"Kane","year":"1977","journal-title":"Clin. Orthop."},{"key":"10.1016\/j.ejpn.2025.02.003_bib7","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.nmd.2009.11.014","article-title":"The Children's hospital of Philadelphia infant test of neuromuscular Disorders (CHOP INTEND): test development and reliability","volume":"20","author":"Glanzman","year":"2010","journal-title":"Neuromuscul. Disord."},{"key":"10.1016\/j.ejpn.2025.02.003_bib8","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1002\/acn3.51276","article-title":"Type I SMA \u2018new natural history\u2019: long\u2010term data in nusinersen\u2010treated patients","volume":"8","author":"Pane","year":"2021","journal-title":"Ann Clin Transl Neurol"},{"key":"10.1016\/j.ejpn.2025.02.003_bib9","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/j.nmd.2021.03.012","article-title":"Age related treatment effect in type II Spinal Muscular Atrophy pediatric patients treated with nusinersen","volume":"31","author":"Coratti","year":"2021","journal-title":"Neuromuscul. Disord."},{"key":"10.1016\/j.ejpn.2025.02.003_bib10","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1002\/ana.25533","article-title":"Nusinersen in type 1 spinal muscular atrophy: twelve-month real-world data","volume":"86","author":"Pane","year":"2019","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.ejpn.2025.02.003_bib11","doi-asserted-by":"crossref","first-page":"135","DOI":"10.3233\/JND-180315","article-title":"Evaluation of children with SMA type 1 under treatment with nusinersen within the expanded access program in Germany","volume":"5","author":"Pechmann","year":"2018","journal-title":"J. Neuromuscul. Dis."},{"key":"10.1016\/j.ejpn.2025.02.003_bib12","doi-asserted-by":"crossref","first-page":"217","DOI":"10.3233\/JND-200533","article-title":"Clinical outcomes in patients with spinal muscular atrophy Type 1 treated with nusinersen","volume":"8","author":"de Holanda Mendon\u00e7a","year":"2021","journal-title":"J. Neuromuscul. Dis."},{"key":"10.1016\/j.ejpn.2025.02.003_bib13","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/s43856-023-00256-2","article-title":"Nusinersen mitigates neuroinflammation in severe spinal muscular atrophy patients","volume":"3","author":"Nuzzo","year":"2023","journal-title":"Commun Med (Lond)."},{"key":"10.1016\/j.ejpn.2025.02.003_bib14","first-page":"1003","article-title":"Neuroinflammation induces neurodegeneration","volume":"1","author":"Kempuraj","year":"2016","journal-title":"J Neurol Neurosurg Spine"},{"key":"10.1016\/j.ejpn.2025.02.003_bib15","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.nmd.2017.11.005","article-title":"Diagnosis and management of spinal muscular atrophy: Part 1: recommendations for diagnosis, rehabilitation, orthopedic and nutritional care","volume":"28","author":"Mercuri","year":"2018","journal-title":"Neuromuscul. Disord."},{"key":"10.1016\/j.ejpn.2025.02.003_bib16","doi-asserted-by":"crossref","first-page":"179","DOI":"10.31083\/j.fbl2706179","article-title":"Physical therapy and nusinersen impact on spinal muscular atrophy rehabilitative outcome","volume":"27","author":"Mirea","year":"2022","journal-title":"Front Biosci-Landmark"},{"key":"10.1016\/j.ejpn.2025.02.003_bib17","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s13023-023-02639-z","article-title":"Areas of improvement in the medical care of SMA: evidence from a nationwide patient registry in Germany","volume":"18","author":"Leibrock","year":"2023","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.ejpn.2025.02.003_bib18","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2021.704928","article-title":"Effect of the COVID-19 pandemic on children with SMA receiving nusinersen: what is missed and what is gained?","volume":"12","author":"Agosto","year":"2021","journal-title":"Front. Neurol."},{"key":"10.1016\/j.ejpn.2025.02.003_bib19","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.braindev.2022.10.006","article-title":"Long-term efficacy of nusinersen and its evaluation in adolescent and adult patients with spinal muscular atrophy types 1 and 2","volume":"45","author":"Iwayama","year":"2023","journal-title":"Brain Dev."},{"key":"10.1016\/j.ejpn.2025.02.003_bib20","doi-asserted-by":"crossref","first-page":"796","DOI":"10.4103\/aian.AIAN_524_20","article-title":"Clinical experience of nusinersen in a broad spectrum of spinal muscular atrophy: a retrospective study","volume":"23","author":"Kim","year":"2020","journal-title":"Ann. Indian Acad. Neurol."},{"key":"10.1016\/j.ejpn.2025.02.003_bib21","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1002\/mus.26769","article-title":"Nusinersen for older patients with spinal muscular atrophy: a real-world clinical setting experience","volume":"61","author":"Veerapandiyan","year":"2020","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.ejpn.2025.02.003_bib22","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1186\/s12883-017-0853-y","article-title":"A qualitative study of perceptions of meaningful change in spinal muscular atrophy","volume":"17","author":"McGraw","year":"2017","journal-title":"BMC Neurol."},{"key":"10.1016\/j.ejpn.2025.02.003_bib23","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1080\/10400435.2019.1586788","article-title":"Communication skills among children with spinal muscular atrophy type 1: a parent survey","volume":"33","author":"Ball","year":"2021","journal-title":"Assist. Technol."},{"key":"10.1016\/j.ejpn.2025.02.003_bib24","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1002\/mus.27950","article-title":"Impact of nusinersen on the health-related quality of life and caregiver burden of patients with spinal muscular atrophy with symptom onset after age 6 months","volume":"68","author":"Lee","year":"2023","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.ejpn.2025.02.003_bib25","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1002\/mus.27204","article-title":"Preserved eye movements in adults with spinal muscular atrophy","volume":"63","author":"Evangelos","year":"2021","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.ejpn.2025.02.003_bib26","first-page":"549","article-title":"Distal spinal muscular atrophy and ophthalmoparesis. A case with selective type 2 fiber hypotrophy","volume":"38","author":"Dubroxsky","year":"1981","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.ejpn.2025.02.003_bib27","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2022.918255","article-title":"Exploratory evaluation of an eye-tracking system in patients with advanced spinal muscular atrophy type I receiving nusinersen","volume":"13","author":"Yae","year":"2022","journal-title":"Front. Neurol."},{"key":"10.1016\/j.ejpn.2025.02.003_bib28","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1164\/rccm.201906-1175LE","article-title":"Effect of nusinersen on respiratory muscle function in different subtypes of type 1 spinal muscular atrophy","volume":"200","author":"LoMauro","year":"2019","journal-title":"Am. J. Respir. Crit. Care Med."}],"container-title":["European Journal of Paediatric Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S109037982500011X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S109037982500011X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T17:39:38Z","timestamp":1762364378000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S109037982500011X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":28,"alternative-id":["S109037982500011X"],"URL":"https:\/\/doi.org\/10.1016\/j.ejpn.2025.02.003","relation":{},"ISSN":["1090-3798"],"issn-type":[{"value":"1090-3798","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Experience of nusinersen treatment in advanced spinal muscular atrophy type 1: Characteristics of late responders with delayed treatment efficacy","name":"articletitle","label":"Article Title"},{"value":"European Journal of Paediatric Neurology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejpn.2025.02.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 European Paediatric Neurology Society. Published by Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}